Literature DB >> 21770855

Tandem plasmapheresis and hemodialysis: efficacy and safety.

María José Pérez-Sáez1, Katia Toledo, Raquel Ojeda, Rodolfo Crespo, Sagrario Soriano, María Antonia Alvarez de Lara, Alejandro Martín-Malo, Pedro Aljama.   

Abstract

BACKGROUND: Hemodialysis (HD) and plasmapheresis (PE) are usually performed independently on patients who require renal replacement therapy. We analyzed our experience using a technique that performs both modalities simultaneously.
METHODS: Thirty-six patients who were treated with 287 tandem PE and HD (TPH) sessions (mean 7.97 ± 5.6 per patient) were included. PE was connected 30 min after HD started. The mean HD blood flow was 313.7 ± 44 mL/min, the mean PE blood flow was 141 ± 25 mL/min, and the duration of TPH was no longer than 240 min. The heparin dose was similar to that used for a standard HD procedure.
RESULTS: In 287 TPH sessions performed, 10.45% experienced minor complications. There were significant changes in mean blood pressure after connection of the PE system. However, these differences were not clinically relevant since patients remained asymptomatic and they did not require saline infusion. At the end of treatment, 38.9% of patients were no longer dependent on dialysis.
CONCLUSIONS: Our results suggest that TPH is a safe and effective treatment that decreases exposure to an extracorporeal circuit, reducing the risks that are associated with anticoagulation agents and improving the comfortability of the patient.

Entities:  

Mesh:

Year:  2011        PMID: 21770855     DOI: 10.3109/0886022X.2011.599912

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

Review 1.  Tandem hemodialysis and plasma exchange.

Authors:  Guido Filler; William F Clark; Shih-Han S Huang
Journal:  Pediatr Nephrol       Date:  2013-09-11       Impact factor: 3.714

2.  Safety and efficacy of tandem hemodialysis and plasma exchange in children.

Authors:  Betti Schaefer; Akos Ujszaszi; Susanne Schaefer; Karl Heinz Heckert; Franz Schaefer; Claus Peter Schmitt
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.